Purpose:
Adjuvant endocrine therapy (AET) for ≥ 5 years is generally recommended for women with hormone receptor-positive breast cancer to reduce cancer recurrence/mortality; however, adherence can be suboptimal. We tested determinants of AET adherence using patient characteristics, treatment pathways, AET initiation timing, and multiple healthcare facility use. An underlying objective was to explore how oncological pathways mirror chronic disease management to monitor adherence and target improvement interventions using administrative datasets.
Methods:
Using patient-linked administrative health data from the Italian Lombardy Region, we identified 33.291 surviving patients starting AET in 2010-2016, with two (22.939 patients) or five years (8400 patients) follow-up, using a ≥ 80% prescription refill approach to measure adherence and logistic regression to test determinants of adherence.
Results:
AET crude adherence falls significantly during follow-up, from 94% at 1 Year to 58% at 5 Years. At 5 Years, patients who were older (>70), prescribed tamoxifen-only (OR 0.69; 95% CI 0.57-0.83; p = 0.0001) vs. aromatase inhibitors-only or therapy switches, treated for depression (OR 0.68; 95% CI 0.60-0.78; p < 0.0001), with surgery performed in high-volume hospitals (OR 0.85; 95% CI 0.75-0.97; p = 0.0116) showed lower adherence. Loyalty, or continued care in the surgical hospital (OR 1.73; 95% CI 1.51-2.00; p < 0.0001), undergoing chemotherapy before AET (OR 2.65; 95% CI 2.02-3.48; p < 0.0001), and earlier AET initiation, positively influenced adherence.
Conclusions:
Chronic disease monitoring using administrative data can help oncologists focus efforts to ensure AET adherence. Results suggest addressing mental health, age, disease severity patient perceptions, timely AET initiation and therapy switches, and encouraging continued follow-up in the same hospital or better care coordination with outside follow-up specialists.
Citing Articles
Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?.
Navarro-Sabate A, Font R, Espinas J, Sola J, Martinez-Soler F, Gil-Gil M
Cancers (Basel). 2025; 17(2).
PMID: 39857981
PMC: 11763350.
DOI: 10.3390/cancers17020200.
Is tamoxifen good enough for the Asian population in ER+ HER2- post-menopausal women with early breast cancer? A nationwide population-based cohort study.
Chang C, Lee Y, Huang C, Lu Y
PLoS One. 2024; 19(11):e0313120.
PMID: 39602456
PMC: 11602078.
DOI: 10.1371/journal.pone.0313120.
Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.
Rassy E, Benvenuti C, Akla S, Di Meglio A, Martin E, Havas J
NPJ Breast Cancer. 2024; 10(1):48.
PMID: 38886406
PMC: 11183231.
DOI: 10.1038/s41523-024-00655-1.
Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.
Yang S, Park S, Bae S, Ahn S, Jeong J, Park K
J Breast Cancer. 2023; 26(4):309-333.
PMID: 37272247
PMC: 10475712.
DOI: 10.4048/jbc.2023.26.e22.
Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.
Kim J, Kim M, Rajan S, Du X, Franzini L, Kim T
Curr Oncol. 2023; 30(4):3800-3816.
PMID: 37185401
PMC: 10136640.
DOI: 10.3390/curroncol30040288.
Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients-a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy.
Kuhn E, Pirruccello J, Boothe J, Li Z, Tosteson T, Stahl J
Breast Cancer Res Treat. 2023; 198(1):31-41.
PMID: 36592233
PMC: 9883310.
DOI: 10.1007/s10549-022-06849-0.
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions.
Rassy E, Bardet A, Bougacha O, Gantzer L, Lekens B, Delaloge S
JAMA Netw Open. 2022; 5(12):e2244849.
PMID: 36459136
PMC: 9719053.
DOI: 10.1001/jamanetworkopen.2022.44849.
Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
En-Nasery-de Heer S, N M F Tromp V, Westerman M, Konings I, Beckeringh J, Boons C
Eur J Cancer Care (Engl). 2022; 31(6):e13749.
PMID: 36300863
PMC: 9786726.
DOI: 10.1111/ecc.13749.
Person-centred support programme (RESPECT intervention) for women with breast cancer treated with endocrine therapy: a feasibility study.
Ahlstedt Karlsson S, Henoch I, Olofsson Bagge R, Wallengren C
BMJ Open. 2022; 12(10):e060946.
PMID: 36198470
PMC: 9535178.
DOI: 10.1136/bmjopen-2022-060946.
Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
Aiello Bowles E, Ramin C, Buist D, Feigelson H, Weinmann S, Veiga L
Breast Cancer Res Treat. 2022; 193(1):203-216.
PMID: 35275285
PMC: 10135399.
DOI: 10.1007/s10549-022-06561-z.
Endocrine adherence in male versus female breast cancer: a seer-medicare review.
Ali A, Xie Z, Stanko L, De Leo E, Hong Y, Bian J
Breast Cancer Res Treat. 2022; 192(3):491-499.
PMID: 35142938
DOI: 10.1007/s10549-022-06536-0.
Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer.
Montagna E, Zagami P, Masiero M, Mazzocco K, Pravettoni G, Munzone E
Patient Prefer Adherence. 2021; 15:2051-2061.
PMID: 34552323
PMC: 8450184.
DOI: 10.2147/PPA.S285768.
RE: Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early stage breast cancer patients.
Li X, Chen H
Breast Cancer Res Treat. 2021; 186(2):585-586.
PMID: 33704617
DOI: 10.1007/s10549-021-06146-2.
Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.
Liu X, Zheng D, Wu Y, Luo C, Fan Y, Zhong X
BMC Cancer. 2021; 21(1):226.
PMID: 33673816
PMC: 7934540.
DOI: 10.1186/s12885-021-07947-w.